| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
156,320,000 |
| Market
Cap: |
6.65(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.26 - $43.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
| Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
| Total People Bought |
0 |
0 |
6 |
6 |
| Total Buy Transactions |
0 |
0 |
6 |
7 |
| Total Shares Sold |
154,667 |
359,132 |
611,027 |
1,200,893 |
| Total Sell Value |
$6,418,967 |
$14,072,755 |
$21,003,717 |
$39,590,443 |
| Total People Sold |
2 |
8 |
8 |
10 |
| Total Sell Transactions |
5 |
21 |
27 |
48 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pfizer Inc |
10% Owner |
– – • |
2020-10-27 |
4 |
B |
$10.00 |
$12,000,000 |
D/D |
1,200,000 |
27,349,211 |
2.45 |
36% |
|
| Edelman Joseph |
Director |
– • – |
2020-10-21 |
4 |
B |
$10.09 |
$435,838 |
I/I |
43,195 |
157,295 |
2.1 |
45% |
|
| Edelman Joseph |
Director |
– • – |
2020-10-20 |
4 |
B |
$10.00 |
$1,141,000 |
I/I |
114,100 |
114,100 |
2.1 |
54% |
|
| Arya Sciences Holdings Ii |
|
• • • |
2020-06-09 |
4 |
A |
$10.00 |
$4,990,000 |
D/D |
499,000 |
499,000 |
|
- |
|
| Altman Michael Seth |
Chief Financial Officer |
• • – |
2020-06-09 |
4 |
A |
$10.00 |
$4,990,000 |
I/I |
499,000 |
499,000 |
|
- |
|
| Stone Adam Leo |
Chief Executive Officer |
• • – |
2020-06-09 |
4 |
A |
$10.00 |
$4,990,000 |
I/I |
499,000 |
499,000 |
|
- |
|
181 Records found
|
|
Page 8 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (0.09%) 
